Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure with Preserved Ejection Fraction (HFpEF)~* Normal left ventricular ejection fraction (≥50%)~* Elevated Left Ventricular filling pressures at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure\>15 mmHg and/or ≥25 mmHg during exercise).~Exclusion Criteria:~* Prior albuterol therapy (within previous 48 hours)~* Current long acting inhaled beta agonist use~* Significant hypokalemia (\<3meq/L)~* Significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis)~* High output heart failure~* Severe pulmonary disease~* Unstable coronary disease~* Constrictive pericarditis~* Restrictive cardiomyopathy~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled albuterol (Type: EXPERIMENTAL): 2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
- Inhaled saline placebo (Type: PLACEBO_COMPARATOR): Inhaled saline through a high efficiency nebulizer -single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).